QGEN Stock Forecast: QIAGEN NV Price Predictions for 2026-2027
The 12 Wall Street analysts covering QIAGEN NV hold a median 12-month price target of $52 — +5.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores QIAGEN NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QGEN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.5% from it.
Of the 20 most recent actions, 9 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | UBS | Maintains | Neutral | $48 → $50 |
| 28 Oct 2026 | Barclays | Downgrade | Equal-Weight | $55 → $53 |
| 26 Oct 2026 | Citigroup | Maintains | Neutral | $45 → $52 |
| 22 Oct 2026 | Baird | Maintains | Outperform | $50 → $52 |
| 22 Oct 2026 | JP Morgan | Downgrade | Neutral | $55 → $52 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $50 → $55 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | $40 → $55 |
| 9 Sept 2026 | UBS | Maintains | Neutral | $52 → $47 |
| 10 Aug 2026 | Citigroup | Maintains | Neutral | $38 → $45 |
| 7 Aug 2026 | Barclays | Maintains | Equal-Weight | $38 → $40 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $45 → $50 |
| 23 June 2026 | Morgan Stanley | Upgrade | Overweight | $40 → $42 |
| 18 May 2026 | Stifel | Maintains | Hold | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
| 29 Apr 2026 | Baird | Upgrade | Outperform | — |
| 29 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 29 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 29 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
| 13 Mar 2026 | Deutsche Bank | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QGEN.
This page is one stock. Monday covers all of them.
QGEN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QGEN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, QIAGEN NV returned +8.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QGEN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 26.7×
- Price / sales
- 4.8×
- Price / book
- 2.9×
- EV / EBITDA
- 14.7×
Cheaper than 33% of US stocks
Cheaper than 22% of US stocks
Cheaper than 31% of US stocks
Cheaper than 35% of US stocks
- Revenue growth (YoY)
- 2.9%
- Earnings growth (YoY)
- −18.8%
- Gross margin
- 63.6%
- Operating margin
- 26.7%
- Net margin
- 18.2%
Higher than 35% of US stocks
Higher than 21% of US stocks
Higher than 77% of US stocks
Higher than 85% of US stocks
Higher than 79% of US stocks
- Return on equity
- 10.8%
- Return on assets
- 5.7%
- Dividend yield
- 0.7%
Higher than 64% of US stocks
Higher than 79% of US stocks
Higher than 12% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
QIAGEN NV has a market value of $10.2B and an enterprise value of $11.1B.
Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: $409.3M, a 19.5% net margin.
Diluted earnings per share, trailing twelve months: $1.98.
Free cash flow in the twelve months to 30 June 2026: $440.6M.
Trailing P/E: 26.7×; forward P/E: 18.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.71%, paying out 19% of earnings.
QIAGEN NV employs 5,400 people — $389K of revenue per employee.
Data provided by Twelve Data
QGEN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QGEN’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own QIAGEN NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QGEN
What is the QGEN stock price forecast for 2026-2027?
The 12 Wall Street analysts covering QIAGEN NV have a median 12-month price target of $52, with estimates ranging from $40 to $53. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is QGEN stock a buy right now?
Of the 12 analysts covering QIAGEN NV, 1 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks QIAGEN NV 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank QGEN?
As at 21 Nov 2026, QIAGEN NV ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
Will QGEN stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +5.5% from the last close, and Ticker Nerd's factor model ranks QIAGEN NV 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the QGEN stock forecast for 2030?
No analyst covering QIAGEN NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $53 over the next 12 months.
How has QGEN stock performed over the past year?
QIAGEN NV returned +8.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does QIAGEN NV do?
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials.
About QIAGEN NV.
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.
CEO Mr. Jonathan M. Pratt · 5,400 employees · Netherlands · https://www.qiagen.com